SEC Company Response from Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Oct 2, 2019
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Oct. 2, 2019 · CIK: 0001645469 · Accession: 0001654954-19-011360
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233303
Letter
Blueprint
Monopar Therapeutics Inc.
Skokie Blvd., Suite 350
Wilmette, Illinois 60091
October 2, 2019
VIA EDGAR
US Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re:
Monopar Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-233303
Ladies and Gentlemen:
In prior correspondence, dated September 30, 2019, Monopar Therapeutics Inc. (the “Company”) requested that the above-referenced Registration Statement be declared effective at 4 p.m., Eastern time, on October 2, 2019 (the “Acceleration Request”). The Acceleration Request is hereby withdrawn by the Company.
Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing.
Very
truly yours,
Monopar
Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm Blueprint Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 October 2, 2019 VIA EDGAR US Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-1 File No. 333-233303 Ladies and Gentlemen: In prior correspondence, dated September 30, 2019, Monopar Therapeutics Inc. (the “Company”) requested that the above-referenced Registration Statement be declared effective at 4 p.m., Eastern time, on October 2, 2019 (the “Acceleration Request”). The Acceleration Request is hereby withdrawn by the Company. Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing. Very truly yours, Monopar Therapeutics Inc. By: /s/ Chandler D. Robinson Name: Chandler D. Robinson Title: Chief Executive Officer